Clinically Oriented Enabling Technologies in Psychedelic Treatment

This week, the Trip Report reviewed how technology may aid in the future of psychedelic treatment.

Specifically, the report investigated three clinically oriented enabling technologies that are being developed by Atai Life Sciences - a German Psychedelics platform company that recently underwent it's IPO listing.

These clinically oriented enabling technologies could hugely aid the way in which psychedelic therapy is provided, via:

  1. Diagnosis & symptom measurement
  2. Care delivery (the administration and observation, not route of delivery, i.e., oral, nasal delivery, etc.)
  3. Preparation and integration
  4. Neurostimulation before, during, or after psychedelic experiences

Ultimately, the post concludes that "the resurgence of interest in psychedelics as tools for healing and transformation will not be limited to the halls of medicine. And neither will the technology."

Follow the link above for access to the entire post, and for more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

Relational and growth outcomes following couples therapy with MDMA for PTSD

Next
Next

Cannabis-induced oceanic boundlessness